AARTIPHARM — Aarti Pharmalabs Share Price
Last trade - 00:00- IN₹63.08bn
- IN₹64.93bn
- IN₹18.53bn
- 38
- 16
- 80
- 38
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.59 | ||
| Price to Tang. Book | 3.76 | ||
| Price to Free Cashflow | 359.06 | ||
| Price to Sales | 3.24 | ||
| EV to EBITDA | 16.33 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 17.03% | ||
| Return on Equity | 13.59% | ||
| Operating Margin | 16.49% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | n/a | n/a | 11,999.43 | 19,452.33 | 18,526.09 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | -20.82 | +11.9 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aarti Pharmalabs Limited is a manufacturer of active pharmaceutical ingredients (API), pharmaceutical intermediates, new chemical entities (NCE), xanthine derivatives, and allied products, situated in India. The Company delivers contract development and manufacturing organization (CDMO) services for drug substance/NCE development and manufacturing for pharmaceutical and biotech firms with a focus on the Ph-I/II/III, launch, and commercial phases. It has dedicated facilities for the production of corticosteroids, cytotoxic medicines, and oncology products. Its range of API products include Ramipril, Quinapril HCL, Budesonide, Bambuterol HCL, Apixaban, Rivaroxaban, Cinacalcet and others. Its range of intermediate products include Abemaciclib Intermediate, Acalabrutinib Intermediate, Afatinib Intermediate, Apalutamide Intermediate, Azathioprine Intermediate, and others. Its Caffeine products include caffeine anhydrous, and caffeine anhydrous (granules).
Directors
- Last Annual
- March 31st, 2024
- Last Interim
- June 30th, 2024
- Incorporated
- November 22nd, 2019
- Public Since
- January 30th, 2023
- No. of Shareholders
- 208,825
- No. of Employees
- 1,627
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 90,626,008
- Address
- MUMBAI, 400080
- Web
- https://www.aartipharmalabs.com/
- Phone
- +91 2269436100
- Contact
- Nikhil Natu
- Auditors
- Gokhale & Sathe
Similar to AARTIPHARM
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
Ajanta Pharma
National Stock Exchange of India
FAQ
As of Today at 19:00 UTC, shares in Aarti Pharmalabs are trading at IN₹696.10. This share price information is delayed by 15 minutes.
Shares in Aarti Pharmalabs last closed at IN₹696.10 and the price had moved by +55.21% over the past 365 days. In terms of relative price strength the Aarti Pharmalabs share price has outperformed the S&P BSE 100 Index by +19.13% over the past year.
There is no consensus recommendation for this security.
Find out moreThe Aarti Pharmalabs dividend yield is 0.43% based on the trailing twelve month period.
Last year, Aarti Pharmalabs paid a total dividend of IN₹3.00, and it currently has a trailing dividend yield of 0.43%. We do not have any data on when Aarti Pharmalabs is to next pay dividends.
We do not have data on when Aarti Pharmalabs is to next pay dividends. The historic dividend yield on Aarti Pharmalabs shares is currently 0.43%.
To buy shares in Aarti Pharmalabs you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹696.10, shares in Aarti Pharmalabs had a market capitalisation of IN₹63.08bn.
Here are the trading details for Aarti Pharmalabs:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: AARTIPHARM
Based on an overall assessment of its quality, value and momentum Aarti Pharmalabs is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aarti Pharmalabs. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +34.65%.
As of the last closing price of IN₹696.10, shares in Aarti Pharmalabs were trading +29.15% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Aarti Pharmalabs PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹696.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Aarti Pharmalabs' directors